Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Tsun-Yung, Lin, Meei-Yun, Coffman, Robert L., Campbell, John D., Traquina, Paula, Lin, Yi-Jiun, Liu, Luke Tzu-Chi, Cheng, Jinyi, Wu, Yu-Chi, Wu, Chung-Chin, Tang, Wei-Hsuan, Huang, Chung-Guei, Tsao, Kuo-Chien, Chen, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676267/
https://www.ncbi.nlm.nih.gov/pubmed/33208827
http://dx.doi.org/10.1038/s41598-020-77077-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676267/
https://www.ncbi.nlm.nih.gov/pubmed/33208827
http://dx.doi.org/10.1038/s41598-020-77077-z

Ejemplares similares